MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.
The -MINE regimen consists of:
- Rituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
- Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
- Ifosfamide - an alkylating antineoplastic agent from oxazafosforine group;
- Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
- Etoposide - a topoisomerase inhibitor.
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| Rituximab | 375 mg/m | IV infusion | Day 1 |
| Mesna | 1330 mg/m | IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide | Days 1-3 |
| Ifosfamide | 1330 mg/m | IV infusion over 1h | Days 1-3 |
| Mitoxantrone | 8 mg/m | IV infusion | Day 1 |
| Etoposide | 65 mg/m | IV infusion over 1h | Days 1-3 |
References
- A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas
- Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.